相似文献
1
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody.
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12400-4. doi: 10.1073/pnas.0603488103. Epub 2006 Aug 8.
2
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354.
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18950-5. doi: 10.1073/pnas.1011036107. Epub 2010 Oct 18.
3
Structure of the complex of an Fab fragment of a neutralizing antibody with foot-and-mouth disease virus: positioning of a highly mobile antigenic loop.
EMBO J. 1997 Apr 1;16(7):1492-500. doi: 10.1093/emboj/16.7.1492.
4
Structural basis of West Nile virus neutralization by a therapeutic antibody.
Nature. 2005 Sep 29;437(7059):764-9. doi: 10.1038/nature03956.
5
Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody.
Nat Commun. 2015 Sep 14;6:8176. doi: 10.1038/ncomms9176.
6
Capturing a flavivirus pre-fusion intermediate.
PLoS Pathog. 2009 Nov;5(11):e1000672. doi: 10.1371/journal.ppat.1000672. Epub 2009 Nov 26.
7
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.
Nat Struct Mol Biol. 2008 Mar;15(3):312-7. doi: 10.1038/nsmb.1382. Epub 2008 Feb 10.
8
Flexibility of the major antigenic loop of foot-and-mouth disease virus bound to a Fab fragment of a neutralising antibody: structure and neutralisation.
Virology. 1999 Mar 15;255(2):260-8. doi: 10.1006/viro.1998.9554.
9
Structural comparison of different antibodies interacting with parvovirus capsids.
J Virol. 2009 Jun;83(11):5556-66. doi: 10.1128/JVI.02532-08. Epub 2009 Mar 25.
10
Structure determination of an Fab fragment that neutralizes human rhinovirus 14 and analysis of the Fab-virus complex.
J Mol Biol. 1994 Jul 8;240(2):127-37. doi: 10.1006/jmbi.1994.1427.
引用本文的文献
1
A Scoping Review of Preclinical Research on Monoclonal Antibody Development for Prophylaxis and Treatment of West Nile Virus Infections.
Viruses. 2025 Jun 12;17(6):845. doi: 10.3390/v17060845.
2
From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity.
Vaccines (Basel). 2025 Apr 24;13(5):449. doi: 10.3390/vaccines13050449.
3
Neutralization Tests for Quantification of Specific Antibodies Against Yellow Fever Virus.
Methods Mol Biol. 2025;2913:79-92. doi: 10.1007/978-1-0716-4458-4_8.
4
Antibody-mediated control mechanisms of viral infections.
Immunol Rev. 2024 Nov;328(1):205-220. doi: 10.1111/imr.13383. Epub 2024 Aug 20.
5
Low-temperature culture enhances production of flavivirus virus-like particles in mammalian cells.
Appl Microbiol Biotechnol. 2024 Feb 28;108(1):242. doi: 10.1007/s00253-024-13064-y.
6
Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy.
Front Immunol. 2023 Aug 10;14:1186063. doi: 10.3389/fimmu.2023.1186063. eCollection 2023.
7
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection.
Viruses. 2022 Nov 10;14(11):2485. doi: 10.3390/v14112485.
8
Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B.
Nat Commun. 2020 Sep 4;11(1):4419. doi: 10.1038/s41467-020-18250-w.
9
Mapping the diverse structural landscape of the flavivirus antibody repertoire.
Curr Opin Virol. 2020 Dec;45:51-64. doi: 10.1016/j.coviro.2020.07.006. Epub 2020 Aug 13.
10
Cryo-EM Studies of Virus-Antibody Immune Complexes.
Virol Sin. 2020 Feb;35(1):1-13. doi: 10.1007/s12250-019-00190-5. Epub 2020 Jan 8.
本文引用的文献
1
Antibody elbow angles are influenced by their light chain class.
J Mol Biol. 2006 Apr 14;357(5):1566-74. doi: 10.1016/j.jmb.2006.01.023. Epub 2006 Jan 25.
2
Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN.
Cell. 2006 Feb 10;124(3):485-93. doi: 10.1016/j.cell.2005.11.042.
3
A model-based parallel origin and orientation refinement algorithm for cryoTEM and its application to the study of virus structures.
J Struct Biol. 2006 Apr;154(1):1-19. doi: 10.1016/j.jsb.2005.06.009. Epub 2005 Dec 5.
4
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection.
J Virol. 2006 Feb;80(3):1290-301. doi: 10.1128/JVI.80.3.1290-1301.2006.
5
West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States.
Annu Rev Med. 2006;57:181-94. doi: 10.1146/annurev.med.57.121304.131418.
6
Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin.
J Biol Chem. 2006 Jan 20;281(3):1352-60. doi: 10.1074/jbc.M506614200. Epub 2005 Nov 7.
7
Structural basis of West Nile virus neutralization by a therapeutic antibody.
Nature. 2005 Sep 29;437(7059):764-9. doi: 10.1038/nature03956.
8
Characterization of neutralizing antibodies to West Nile virus.
Virology. 2005 May 25;336(1):70-82. doi: 10.1016/j.virol.2005.02.020.
9
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.
Nat Med. 2005 May;11(5):522-30. doi: 10.1038/nm1240. Epub 2005 Apr 24.
10
Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.
J Gen Virol. 2005 Feb;86(Pt 2):405-412. doi: 10.1099/vir.0.80411-0.
Zotero 插件